Early relapse prediction after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia (ALL) using lineage‐specific chimerism analysis-Reference-Cited by-同舟云学术

Early relapse prediction after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia (ALL) using lineage‐specific chimerism analysis

Published:2022-09-19 Issue:4 Volume:3 Page:1277-1286
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Lindahl Hannes¹²^ORCID,Valentini Davide³,Vonlanthen Sofie¹,Sundin Mikael⁴⁵,Björklund Andreas T.³,Mielke Stephan⁶,Hauzenberger Dan¹

Affiliation:

1. Clinical Immunology and Transfusion Medicine Karolinska University Hospital Stockholm Sweden

2. Department of Clinical Neuroscience Karolinska Institutet Stockholm Sweden

3. Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST) Karolinska University Hospital Stockholm Sweden

4. Pediatric Hematology Immunology and HCT Astrid Lindgren Children's Hospital Karolinska University Hospital Stockholm Sweden

5. Pediatrics CLINTEC Karolinska Institutet Stockholm Sweden

6. Department of Cell Therapy and Allogeneic Stem Cell Transplantation (CAST) Department of Laboratory Medicine (LabMED) Karolinska University Hospital and Institutet Karolinska Comprehensive Cancer Center Stockholm Sweden

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.568

Reference24 articles.

1. Indications for Allogeneic HCT in Adults with Acute Lymphoblastic Leukemia in First Complete Remission

2. Acute Lymphoblastic Leukemia in Children

3. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group

4. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial

5. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children